Redeye comments on the first deliveries of the new Carbonhand to patients and is happy to see a good...
Redeye endorses the news that Egetis Therapeutics has conducted a directed share issue of SEK210m an...
Redeye shares its preview of Sedana Medical’s Q4 2022 results, due on February 16.
Redeye shares its preview of BONESUPPORT’s Q4 2022e results and anticipates another record quarter.
Dags för Q4’22-rapport Vi förväntar oss en siffermässigt relativt odramatisk rapport för Q4’22 den 2...
Redeye states its view on today’s December ARR update from Hoylu that closing its Q4 2022 figures.
The upgrade implies Q4 was a lot better than we previously estimated but also suggests further impro...
Mangold Insight initiate coverage of the biotechnology company Biosergen with a buy recommendation a...
Redeye comments on the subscription price for the ongoing rights issue - which was set below Redeye'...
Elanders presented yet another solid report for Q4 2022, growing adjusted EBIT by 37% y/y.
Duearitys certifieringsorgan Intertek meddelade den 20 januari att Tinearity G1 kommer att erhålla C...
Lipigon aviserade under förra veckan positiva säkerhetsdata med Lipisense i klinisk fas I.
Redeye is positively surprised by today’s news that Alelion and Exide Technologies have started a di...
Good momentum for its leased-capacity business We remove Ovzon-3 from '23e as we turn more prudent 1...
Q4 report due on Thursday 16 February We expect net sales of SEK 67m, up 49% y-o-y New CEO to start ...
Redeye sees the FDA's fast track designation for EVX-01 as a validation of the personalised vaccin a...
I november 2022 rapporterade AcouSort att bolaget ingått ett samarbete med ett globalt life science-...
Kraftig tillväxt till följd av höga investeringar i marknadsföring… Nettoomsättningen i kvartalet up...
